EliteImmune
Biotechnology company focused on accelerated discovery and development of fully human therapeutic antibodies for infectious disease, with expanding programs in oncology and aging. Operates integrated wet‑lab and computational platforms to isolate, characterize, engineer, and supply antibodies, recombinant proteins, cell lines and associated bioanalytical services. Maintains research sites in the U.S. (Gaithersburg, MD) and China (Tianjin) and seeks collaborative partnerships for R&D, licensing and development.
Industries
Nr. of Employees
small (1-50)
EliteImmune
Gaithersburg, Maryland, United States, North America
Products
Custom recombinant antibodies (research and development)
Production and supply of expressed and purified recombinant antibodies derived from internal discovery campaigns or custom projects.
Recombinant viral proteins (e.g., receptor or RBD proteins)
Purified recombinant viral antigens and receptor proteins for ELISA, binding assays and immunogen design.
Pseudotyped viral particles (research use)
Vesicular stomatitis virus (VSV)-based pseudotyped particles for neutralization and entry assays.
SARS-CoV-2
Pseudotype virus reagents for SARS-CoV-2 research and assay development.
SARS-CoV-2 VSV-Pseudotype virus
Pseudotype virus reagents for SARS-CoV-2 research and assay development.
SARS-VSV-Pseudotype virus
Pseudotype virus reagents for SARS research and assay development.
Custom recombinant antibodies (research and development)
Production and supply of expressed and purified recombinant antibodies derived from internal discovery campaigns or custom projects.
Recombinant viral proteins (e.g., receptor or RBD proteins)
Purified recombinant viral antigens and receptor proteins for ELISA, binding assays and immunogen design.
Pseudotyped viral particles (research use)
Vesicular stomatitis virus (VSV)-based pseudotyped particles for neutralization and entry assays.
SARS-CoV-2
Pseudotype virus reagents for SARS-CoV-2 research and assay development.
SARS-CoV-2 VSV-Pseudotype virus
Pseudotype virus reagents for SARS-CoV-2 research and assay development.
SARS-VSV-Pseudotype virus
Pseudotype virus reagents for SARS research and assay development.
Services
Collaborative and sponsored discovery programs that identify human monoclonal antibody leads from donor B cells using integrated wet‑lab and computational platforms.
Collaborative and sponsored discovery programs that identify human monoclonal antibody leads from donor B cells using integrated wet‑lab and computational platforms.
Expertise Areas
- Therapeutic antibody discovery
- Antibody engineering and optimization
- Infectious disease therapeutics
- Vaccine antigen design
Key Technologies
- Single‑cell B cell sorting
- Single‑cell immunoglobulin sequencing
- Antibody cloning and recombinant expression
- Mammalian (HEK/CHO), insect and bacterial expression systems
News & Updates
Entered into a collaborative research agreement with a partner to identify and characterize monoclonal antibodies targeting Staphylococcus aureus for therapeutic and diagnostic use.
Signed an exclusive licensing agreement to develop a broadly neutralizing pan‑ebolavirus monoclonal antibody for regional development.
Leased and developed a research laboratory space in Gaithersburg as part of expansion into the BioHealth Capital Region.
Publication reporting post‑exposure immunotherapy efficacy in nonhuman primates for ebolaviruses and Marburg virus.
Structural biology study describing mechanisms of broad ebolavirus neutralization by a human monoclonal antibody.
Method and application article describing single B cell sorting and monoclonal antibody cloning workflows in a model organism.
Entered into a collaborative research agreement with a partner to identify and characterize monoclonal antibodies targeting Staphylococcus aureus for therapeutic and diagnostic use.
Signed an exclusive licensing agreement to develop a broadly neutralizing pan‑ebolavirus monoclonal antibody for regional development.
Leased and developed a research laboratory space in Gaithersburg as part of expansion into the BioHealth Capital Region.
Publication reporting post‑exposure immunotherapy efficacy in nonhuman primates for ebolaviruses and Marburg virus.
Structural biology study describing mechanisms of broad ebolavirus neutralization by a human monoclonal antibody.
Method and application article describing single B cell sorting and monoclonal antibody cloning workflows in a model organism.